TYRA (Tyra Biosciences) Total Assets: $412.04 Mil (As of Mar. 2026)


TYRA Tyra Biosciences Inc TYRA
28 GF Score
Price $31.88
! 2 Warning Signs
View Full Analysis

What is Tyra Biosciences Total Assets?

Tyra Biosciences TYRA +3.07% 28 Total Assets is $412.04 Mil as of Mar. 2026. GuruFocus rates TYRA with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Tyra Biosciences's Total Assets for the quarter that ended in Mar. 2026 was $412.04 Mil.

During the past 12 months, Tyra Biosciences's average Total Assets Growth Rate was 20.30% per year. During the past 3 years, the average Total Assets Growth Rate was 21.10% per year. During the past 5 years, the average Total Assets Growth Rate was 91.70% per year.

During the past 7 years, Tyra Biosciences's highest 3-Year average Total Assets Growth Rate was 229.10%. The lowest was 21.10%. And the median was 137.55%.

Total Assets is connected with ROA %. Tyra Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -45.27%. Total Assets is also linked to Revenue through Asset Turnover. Tyra Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Tyra Biosciences  (NAS:TYRA) Total Assets Explanation

Total Assets is connected with ROA %.

Tyra Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-157.22/( (282.609+412.04)/ 2 )
=-157.22/347.3245
=-45.27 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Tyra Biosciences's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (282.609+412.04)/ 2 )
=0/347.3245
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Tyra Biosciences Total Assets Related Terms

Tyra Biosciences Total Assets Historical Data

* Premium members only.

The historical data trend for Tyra Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tyra Biosciences Total Assets Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 306.70 266.18 225.86 363.56 282.61

Tyra Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 343.48 321.50 301.85 282.61 412.04
TYRA
28GF Score
Tyra Biosciences Inc TYRA
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tyra Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Tyra Biosciences's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=259.177+23.432
=282.61

Tyra Biosciences's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=387.575+24.465
=412.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $412.04 Mil mean?
Tyra Biosciences (TYRA) has a Total Assets of $412.04 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Tyra Biosciences and its competitors.
Is Tyra Biosciences' Total Assets too high?
Tyra Biosciences' current Total Assets is $412.04 Mil. Overall, Tyra Biosciences has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Tyra Biosciences' Total Assets compare to ZLAB and OCUL?
Tyra Biosciences' Total Assets of $412.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Tyra Biosciences and its competitors. Tyra Biosciences's current Total Assets is $412.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tyra Biosciences stock overvalued right now?
Tyra Biosciences (TYRA) has a current Total Assets of $412.04 Mil. The current Total Assets is $412.04 Mil. Tyra Biosciences' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Tyra Biosciences (TYRA), the current Total Assets is $412.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tyra Biosciences Business Description

Address 2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
28GF Score

Get the complete analysis for TYRA

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.88
Price